Alterity Therapeutics (ATHE) Presents Positive Phase 2 Data for ATH434
Alterity Therapeutics Limited (NASDAQ:ATHE) is one of the best performing ASX stocks in 2025.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Citadel Investment Group Ken Griffin | 0 | $0 | 0% |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| 0.5000 (reported; USD unavailable) | 47,620 | USD value unavailable | 191,340 | 2026-08-31 | Filing |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 75,443 | $275,367 | 0.03% | |
| 2. | 62,000 | $226,300 | 0% | |
| 3. | 58,460 | $213,379 | 0% | |
| 4. | 57,242 | $208,933 | 0% | |
| 5. | 15,349 | $56,024 | 0% |